MedTrace Logo

Anemia in Systemic Lupus Erythematosus Specially Refractory Type

NCT06210295 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2024-06-06

No results posted yet for this study

Summary

Systemic lupus erythroematosis (SLE) is a systemic autoimmune disease with multisystemic involvement. The condition has several phenotypes, with varying clinical presentations from mild mucocutaneous manifestations to multiorgan and severe central nervous system involvement. Several immunopathogenic pathways play a role in the development of SLE. Despite recent advances in technology and understanding of the pathological basis and risk factors for SLE, the exact pathogenesis is still not well known. Diagnosis of SLE can be challenging, and while several classification criteria have been posed, their utility in the clinical setting is still a matter of debate. Management of SLE is dictated by organ system involvement. Despite several agents shown to be efficacious in treating SLE, the disease still poses significant morbidity and mortality risks in patients\[1\].

Haematological abnormalities are common in systemic lupus erythroematosis. Anemia is found in about 50% of patients.

Conditions

  • Refractory Anemia in Systemic Lupus Erythematosis

Interventions

COMBINATION_PRODUCT

Laboratory investigtions

To study causes of anemia in SLE in our environment and causes of refractory type and its relation to bone marrow affection and different drugs used in SLE

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-09
Primary Completion
2024-09-20
Completion
2024-12-20
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06210295 on ClinicalTrials.gov